Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios.
about
Namibia's transition from whole blood-derived pooled platelets to single-donor apheresis platelet collectionsIntroducing Pathogen Reduction Technology in Poland: A Cost-Utility AnalysisHuman Immunodeficiency Virus (HIV).An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different Western countries.Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing.Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa.Contrasting HCV and HIV seroepidemiology in 11 years of blood donors screening in Brazil.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA.Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.Inclusion of human immunodeficiency virus Type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: a multicenter performance evaluation study.Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany.Changes in the prevalence, incidence and residual risk for HIV and hepatitis C virus in Southern Brazilian blood donors since the implementation of NAT screening.Predonation screening of candidate donors and prevention of window period donations.NAT yield for human immunodeficiency and hepatitis C viruses in Brazilian blood donors: preliminary results.Screening blood donors for hepatitis C virus: the challenge to consider cost-effectiveness.Sensitivity and specificity of a new automated system for the detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus nucleic acid in blood and plasma donations.First approach in the implementation of the nucleic acid amplification test in a resource-limited blood bank in Mexico.
P2860
Q33420773-381AA1AC-FB4F-44C0-B4EC-BA4EF1F6F969Q35789569-51B74A02-D131-45AA-8360-3D4F61F35579Q37045832-1659F513-DBDE-48AC-8F80-DBBF90DAD39FQ38714326-28AD6842-8839-47B2-BDBB-77E82BA7CB77Q39347172-CC5F18EF-18A5-42A8-B518-F24475F814F0Q40078433-29D36C2E-D7D6-4750-98D5-9CA20A2471B4Q40194957-41E0EAA8-4766-4D29-8028-17391C79C54CQ40942917-4F4B1D4B-C203-4B76-BAAC-0D9283A076A5Q40962292-B70B1C1C-DC9B-424D-8520-8C238A01E59CQ41332068-5D2F4B93-8EBF-4FC4-B92D-4FCB7A11389CQ41647666-E93B7336-9DA7-41AE-8CCE-DBBFB4D8647AQ41692988-F2AE2285-7825-40A3-9080-8FA88E7A5B7AQ41736265-B952DAB7-0BDF-47B7-AB6B-1A5EAA600AEFQ42199551-DD97ED20-0253-4782-B9C2-D94842502F86Q43047121-EB7D29B9-E057-4032-A9E3-85CC7CD59921Q44878545-43E0C31C-B245-4B1E-ACD4-6631183980B6Q47564410-39E3105F-F279-44B7-839C-A653ABCED4F9Q47946392-D7006CA0-7C07-41B2-A24A-60D922FB39B1
P2860
Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Prevalence of human immunodefi ...... ternative screening scenarios.
@en
Prevalence of human immunodefi ...... ternative screening scenarios.
@nl
type
label
Prevalence of human immunodefi ...... ternative screening scenarios.
@en
Prevalence of human immunodefi ...... ternative screening scenarios.
@nl
prefLabel
Prevalence of human immunodefi ...... ternative screening scenarios.
@en
Prevalence of human immunodefi ...... ternative screening scenarios.
@nl
P2093
P2860
P356
P1433
P1476
Prevalence of human immunodefi ...... ternative screening scenarios.
@en
P2093
Brian Custer
International NAT Study Group
Nico Lelie
Roberta Bruhn
Steven Kleinman
P2860
P304
P356
10.1111/TRF.12299
P433
P577
2013-06-19T00:00:00Z